[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100451632":3},{"organization":4,"armGroups":7,"interventions":12,"overallOfficials":17,"centralContacts":18,"locations":28,"responsibleParty":85,"collaborators":17,"id":87,"slug":17,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":17,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":109,"whyStopped":17,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"University Hospital, Caen","OTHER",[8],{"label":9,"type":6,"description":9,"interventionNames":10},"Patients with AML",[11],"Other: Bone osteodensitometry",[13],{"type":6,"name":14,"description":15,"armGroupLabels":16,"otherNames":17},"Bone osteodensitometry","Evaluation of bone osteodensitometry",[9],null,[19,24],{"name":20,"role":21,"phone":22,"phoneExt":17,"email":23},"Agathe FARGE, PhD","CONTACT","+33 2.31.27.21.40","farge-a@chu-caen.fr",{"name":25,"role":21,"phone":26,"phoneExt":17,"email":27},"DRCI secretary","+33.2.31.06.57.81","drci-sec@chu-caen.fr",[29,46,57,71],{"facility":30,"status":17,"city":31,"state":17,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Chu Amiens","Amiens","80054","France","FR",{"type":36,"coordinates":37},"Point",[38,39],2.3,49.9,{"lat":39,"lon":38},[42],{"name":43,"role":21,"phone":44,"phoneExt":17,"email":45},"MAROLLEAU Jean-Pierre, MD\u002FPhD","+33 3.22.45.59.20","marolleau.jean-pierre@chu-amiens.fr",{"facility":47,"status":17,"city":48,"state":17,"zip":49,"country":33,"countryCode":34,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"CHU CAEN","Caen","14033",{"type":36,"coordinates":51},[52,53],-0.35912,49.18585,{"lat":53,"lon":52},[56],{"name":20,"role":21,"phone":22,"phoneExt":17,"email":23},{"facility":58,"status":17,"city":59,"state":17,"zip":60,"country":33,"countryCode":34,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Chu Lille","Lille","59000",{"type":36,"coordinates":62},[63,64],3.05512,50.63391,{"lat":64,"lon":63},[67],{"name":68,"role":21,"phone":69,"phoneExt":17,"email":70},"Isabelle LEGROUX, PhD","+33 3.20.44.59.62","Isabelle.legroux@chru-lille.fr",{"facility":72,"status":17,"city":73,"state":17,"zip":74,"country":33,"countryCode":34,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Chu Rouen","Rouen","76038",{"type":36,"coordinates":76},[77,78],1.09932,49.44313,{"lat":78,"lon":77},[81],{"name":82,"role":21,"phone":83,"phoneExt":17,"email":84},"Fabrice JARDIN, MD\u002FPhD","+33 2.32.08.24.51","fabrice.jardin@rouen.fnclcc.fr",{"type":86,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100451632",false,"NCT05161026","Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry","Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry Coupled With FRAX \u002F TBS in Allo-HSCT","REMODALLO","Inclusion Criteria:\n\n* Cytological diagnosis of acute myeloid leukemia (AML) with indication for a first-line allo-HSCTs transplant\n* Patient affiliated to the social security system\n* For women of childbearing age, use of reliable contraception throughout the study in accordance with the CPR of the drugs used.\n* The patient must be able to comply with study visits and per protocol procedures\n* Patient who has been informed of the study and has signed his informed consent\n\nExclusion Criteria:\n\n* Person under guardianship or curatorship, or unable to understand the purpose of the study.\n* Hematologic malignancies other than AML\n* History of neoplasia with bone involvement (sarcoma, multiple myeloma, metastasis...) and\u002For any solid cancer less than 5 years old\n* History of fracture of the femoral neck prior to the diagnosis of hematologic malignancies\n* Known bone involvement related to AML at diagnosis\n* Primary or secondary osteoporosis known to the diagnosis of hematologic malignancies\n* Corticotherapy \\> 3 months at a dose \\> 7.5mg\u002Fday prior to the diagnosis of hematological disease\n* Autograft or anterior allograft\n* Pathologies influencing bone metabolism: known inflammatory rheumatism (rheumatoid arthritis, ...), primary hyperparathyroidism, chronic renal failure (GFR \\\u003C or = at 30ml \u002F min \u002F 1.73m2)\n* Pregnant or lactating woman","ALL","18 Years","75 Years",{"count":98,"type":99},120,"ESTIMATED","INTERVENTIONAL",[102],"NA","Evaluation of variation of mineral density and bone microarchitecture after allogeneic HSCTs transplant in hematologic malignancies. Comparison with the general population.",[105],"Myeloid Leukemia, Acute",[107,108],"allo-HSCTs transplant","osteoporosis","NOT_YET_RECRUITING","2021-12-06",{"date":112,"type":113},"2021-12-16","ACTUAL",{"date":115,"type":99},"2021-12-10",{"date":117,"type":99},"2027-12-01",{"name":5,"class":6},4]